Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab

Natalizumab Reduces Clinical and MRI Activity in Multiple Sclerosis Patients with High Disease Activity: Results from a Multicenter Study in Switzerland

(2010) Norman Putzki et al.   EUROPEAN NEUROLOGY

Neurofilament light as a prognostic marker in multiple sclerosis

(2010) Jonatan Salzer et al.   Multiple Sclerosis Journal

Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis

(2009) N. Putzki et al.   EUROPEAN JOURNAL OF NEUROLOGY

The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers

(2009) M. Khademi et al.   EUROPEAN JOURNAL OF NEUROLOGY

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

(2009) Eva Havrdova et al.   LANCET NEUROLOGY

Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid

(2009) J. Mellergård et al.   Multiple Sclerosis Journal

Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS

(2009) F. Sellebjerg et al.   NEUROLOGY

Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis

(2009) C. E. Teunissen et al.   NEUROLOGY

Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis

(2007) K. Rejdak et al.   Multiple Sclerosis Journal